The recent first global approval of baloxavir marboxil has been reviewed in detail in the First Global Approval report in Adis journal Drugs, based on the development milestones tracked in AdisInsight. Japan was first country to approve baloxavir marboxil in February 2018, under Sakigake fast track review. The agent is being jointly developed by by two persons and was approved for the treatment of influenza types A and B in pediatric and adult patients.
Baloxavir marboxil is dispensed as a convenient oral tablet, it is a cap-dependent endonuclease inhibitor that blocks influenza virus proliferation by inhibiting the initiation of mRNA synthesis. The recommended single oral dose of baloxavir marboxil, taken as soon as possible after the first onset of symptoms, is expected to improve compliance. It is believed that the improved compliance and the novel mechanism of action will prevent…
